A C.D.C. panel will meet today on the Johnson & Johnson vaccine pause. The U.S. government is likely to end the pause if the panel says the vaccine’s benefits outweigh the potential risk.
|
A C.D.C. panel will meet today on the Johnson & Johnson vaccine pause. The U.S. government is likely to end the pause if the panel says the vaccine’s benefits outweigh the potential risk.
|